Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.21 USD | -2.49% | +0.97% | +91.44% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 372.46 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+91.44% | 2.3B | C | ||
+20.59% | 68.31B | A- | ||
-1.02% | 48.49B | A- | ||
+23.82% | 44.42B | B+ | ||
+30.26% | 28.29B | A- | ||
+7.56% | 19.12B | C+ | ||
+10.55% | 16.64B | B+ | ||
-5.73% | 16B | B+ | ||
-21.45% | 15.84B | A- | ||
-20.45% | 13.51B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ASPN Stock
- Ratings Aspen Aerogels, Inc.